Navigation Links
NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results

Milestone Payment from Alcon and Initial Payments from New Galderma Collaboration Resulted in Positive Cash-Flow for the Quarter

EMERYVILLE, Calif., May 18 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a mid-stage biopharmaceutical company developing first-in-class anti-infective products for the treatment and prevention of a wide range of infections without causing resistance, reported today its financial results and operational highlights for the first quarter of 2009 ended March 31, 2009.

License and collaboration revenue for the first quarter of 2009 increased 75% to $2.6 million from $1.5 million for the first quarter of 2008. This revenue consisted almost exclusively of amounts earned under license and collaboration agreements with Alcon, Inc. (NYSE: ACL), a leader in the discovery, development, and commercialization of pharmaceutical products, in particular for the treatment of eye and ear infections and for contact lens care, commencing in August of 2006, and most recently, Galderma S.A, the leading dermatology company in the world. Payments from Alcon were related to on-going research and development support and a milestone payment triggered by the clearance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). During this quarter, a license agreement and collaboration was entered into with Galderma S.A., a leader in the discovery, development, and commercialization of pharmaceutical products and medical devices for the prevention and treatment of skin diseases, for the development of the Aganocide(R) compounds for certain dermatological indications. Under the terms of the agreement, NovaBay received an initial payment and also the first of committed monthly payments in support of development of compounds for acne and eventually for impetigo.

The net loss for the first quarter of 2009 was $(0.3) million, or $(0.01) per share, compared to a net loss of $(2.7) million, or $(0.13) per share, reported for the first quarter of 2008. As of March 31, 2009, the company's cash, cash equivalents and short-term investments totaled $12.9 million, up from $12.1 million at December 31, 2008. The increase was largely due to receipt of milestone payments from Alcon and upfront payments from Galderma, as well as reduced spending on overhead and delayed research and development costs.

"We believe the first quarter of 2009 was one of continued accomplishment for NovaBay as we achieved business development and clinical progress in advancing our first-in-class Aganocide(R) compounds that are designed to mimic the human body's natural defense against infection without developing resistance," said Dr. Ron Najafi, chairman and chief executive officer of NovaBay. "Our collaboration with Galderma for the Aganocides in major dermatological conditions further validates the potential for our novel, potent anti-infectives. At the same time, our pipeline continued to advance during the quarter, and we recently announced an agreement with Professors Nagl and Gottardi of Medical University of Innsbruck - Austria, pioneers in the clinical evaluation of the endogenous, unstable molecule upon which NovaBay's proprietary Aganocides are based, to broaden our intellectual property portfolio and expand the clinical opportunities for the Aganocides."

First Quarter 2009 and Recent Key Achievements

  • NovaBay's alliance with Alcon, Inc. in the ophthalmic, otic and sinusitis fields continues to advance. Alcon initiated a Phase I clinical trial of NVC-422 (N,N-dichloro-2,2-dimethyltaurine), NovaBay's lead Aganocide compound, after receiving clearance of an IND application from the FDA in January. The IND clearance triggered a milestone payment of $1 million from Alcon to NovaBay.

  • In March 2009, NovaBay announced a global agreement with Galderma, S.A. to develop and commercialize Aganocide compounds for all major dermatological conditions, excluding onychomycosis (nail fungus). Under the terms of the agreement, NovaBay expects to receive up to $50 million from Galderma upon achievement of certain development and regulatory milestones related to the acne and impetigo indications and escalating double digit royalties on future net sales of products. Galderma will be responsible for the development costs of the acne and other indications, except in Japan, and for the ongoing development program for impetigo, upon the achievement of a specified milestone.

  • NovaBay also announced in March new data presented at the American Academy of Dermatology 67th Annual Meeting that showed NVC-422 achieved significant anti-mycological efficacy in-vivo in treating subcutaneous dermatophyte infections based on an established pre-clinical model. Importantly, these data combined with the past preclinical work that showed NVC-422 kills P. acne in the follicle which strongly suggests that NVC-422 may be a potent and well-tolerated treatment for acne and numerous other serious skin infections.

  • In April 2009, NovaBay announced an exclusive agreement with Professors Markus Nagl M.D. and Waldemar Gottardi, Ph.D. of the Medical University of Innsbruck, Austria that broadens NovaBay's intellectual property portfolio and could expand clinical opportunities and accelerate clinical timelines for the Aganocide compounds. Under the terms of the agreement, NovaBay has an exclusive license to a broad portfolio of patent applications, as well as exclusive pre-clinical and clinical research data on N-chlorotaurine (NCT), a natural antimicrobial produced by the body's white blood cells which is the biological basis for NovaBay's Aganocides, in multiple disease indications. In addition, NovaBay also owns the rights to successful human proof of concept trials of NCT in otitis externa (ear infection) and viral conjunctivitis (pink eye) that is expected to provide guidance for NovaBay's and its partners' future clinical programs.

First Quarter 2009 Financial Results

License and collaboration revenue for the first quarter of 2009 increased 75% to $2.6 million from $1.5 million for the first quarter of 2008. License and collaboration revenue consists of the amortization of the upfront technology access fees previously paid, and reimbursements for the funding of research and development activities, and payments for milestones from Alcon and Galderma.

The net loss for the first quarter of 2009 was $(0.3) million, or $(0.01) per share, compared to a net loss of $(2.7) million, or $(0.13) per share, reported for the first quarter of 2008.

Research and development expenses for the quarter ended March 31, 2009 totaled $1.4 million, compared to $2.6 million for the quarter ended March 31, 2008. The decrease was due to budget reductions at year end 2008 resulting in decreased headcount, and delayed research, development, and clinical expenses. However, the company expects to incur increasing research, development and clinical expenses in the remainder of 2009 as programs to develop product candidates move forward, both independently and in collaboration with Alcon and now Galderma.

General and administrative expenses for the quarter ended March 31, 2009 were $1.6 million, compared to $1.7 million in the comparable 2008 period. Employee costs related to general and administrative expenses decreased as a result of staff reductions at year end 2008. Professional services costs increased primarily as a result of increased Sarbanes-Oxley implementation and year end audit costs.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a mid-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide compounds, first-in-class, novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without causing resistance. NovaBay has internal development programs aimed at addressing hospital and respiratory infections. The company has a licensing and research collaboration agreement with Alcon, Inc. for use of its Aganocide compounds in the eye, ear and sinus, and in contact lens care solutions. NovaBay has entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. NovaBay(R) and Aganocide(R) are trademarks of NovaBay Pharmaceuticals, Inc. For more information on NovaBay, visit www.

Forward-Looking Statements

This release contains forward-looking statements, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. Statements regarding NovaBay's expectations that it will receive from Galderma up to $50 million upon achievement of certain development and regulatory milestones, NovaBay's expectations regarding its future research and development expenses in 2009, and NovaBay's expectations that its owning rights to successful human proof of concept trials of NCT in otitis externa (ear infection) and viral conjunctivitis (pink eye) will provide guidance for NovaBay's and its partners' future clinical programs, as well as other statements that relate to future events or results, are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to: the risk that milestones and net sales may not be achieved under the Galderma agreement; the risk that NovaBay may incur unexpected charges or need to or determine to engage in research and development not previously planned, which will cause NovaBay's research and development expenses to be greater than it expects; risks and uncertainties relating to difficulties or delays in discovery, development, testing, production and marketing of the company's product candidates; unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates; the uncertainty of patent protection for the company's intellectual property or trade secrets; the company's ability to obtain additional financing as necessary; results obtained in animal models may not be obtained in humans; and the risk of unexpected delays in the regulatory process which may delay the commencement or completion of clinical trials. Other risks relating to NovaBay and Aganocide(R) compounds, including risks that could cause actual results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Annual Report on Form 10-K for the period ended December 31, 2008, under the caption "Risk Factors" in Item 1A of Part I of that report, filed with the Securities and Exchange Commission on March 31, 2009. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.


    NovaBay Pharmaceuticals, Inc.
    Thomas J. Paulson, 510-899-8809
    Chief Financial Officer

    Invigorate Communications
    Investor Relations:
    Gregory Gin, 908-376-7737

    Media Relations:
    Mariesa Kemble, 608-850-4745

                          NOVABAY PHARMACEUTICALS, INC
                    (formerly NovaCal Pharmaceuticals Inc.)
                        (a developmental stage company)

                           CONSOLIDATED BALANCE SHEETS
                      (in thousands, except per share data)

                                                    December 31, March 31,
                                                       2008        2009
        Current assets:
           Cash and cash equivalents                   $12,099  $10,243
           Short-term investments                            -    2,631
           Prepaid expenses and other current assets       414      684
           Total current assets                         12,513   13,558
        Property and equipment, net                      1,456    1,400
        TOTAL ASSETS                                   $13,969  $14,958

        Current liabilities:
           Accounts payable                               $406     $367
           Accrued liabilities                           1,166    1,075
           Capital lease obligation                         42       39
           Equipment loan                                  366      376
           Deferred revenue                              2,500    3,836
           Total current liabilities                     4,480    5,693
        Capital lease obligation - non-current               7        -
        Equipment loan - non-current                       470      372
        Deferred revenue - non-current                   1,667    1,392
           Total liabilities                             6,624    7,457
     Commitments and Contingencies
     Stockholders' Equity:

           Common stock, $0.01 par value; 65,000  and
            65,000 shares authorized at December 31,
            2008 and March 31, 2009, respectively;
            21,471 and 21,662 shares issued and
            outstanding at December 31, 2008 and March
            31, 2009, respectively                         215      217

        Additional paid-in capital                      33,718   34,199
        Accumulated other comprehensive income (loss)        -       (8)
        Accumulated deficit during development stage   (26,588) (26,907)
           Total stockholders' equity                    7,345    7,501

                              NOVABAY PHARMACEUTICALS, INC
                         (formerly NovaCal Pharmaceuticals Inc.)
                             (a developmental stage company)

                           (in thousands, except per share data)

                                                                    July 1,
                                                                   (date of
                                               Three Months          stage
                                                  Ended           inception)
                                                 March 31,        to March 31,
                                             2008         2009       2009
                                         (unaudited)  (unaudited) (unaudited)

        License and collaboration revenue   $1,492     $2,611       $16,779
        Total revenue                        1,492      2,611        16,779

     Operating Expenses:
        Research and development             2,647      1,361        26,368
        General and administrative           1,684      1,579        18,544
        Total operating expenses             4,331      2,940        44,912

     Other income, net                         163         11         1,240

     Net loss before income taxes           (2,676)      (318)      (26,893)
     Provision for income taxes                 (2)         -           (14)
     Net loss                              $(2,678)     $(318)     $(26,907)

     Net loss per share:
        Basic and diluted                   $(0.13)    $(0.01)
     Shares used in per share calculations:
        Basic and diluted                   21,288     21,620

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NovaBay Pharmaceuticals Scientific Advisor Receives American Chemical Societys Highest Award
2. NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
3. NovaBay announces third quarter 2007 financial results
4. NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
6. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
7. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
8. Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
9. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
10. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
11. Alseres Pharmaceuticals, Inc. Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements
Post Your Comments:
(Date:11/25/2015)... ... 25, 2015 , ... Students and parents have something to be thankful for ... Real Impact awards. California Casualty is proud to support the contest designed ... and reckless driving, the number one killer of young drivers. , Almost 1,000 ...
(Date:11/24/2015)... PA (PRWEB) , ... November 24, 2015 , ... ... now certified to offer their patients the many benefits of the revolutionary BIOLASE ... the sharp cutting and scraping tools traditionally used by a dentist in ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a wide ... Angela Wolfman and Dr. Kedar S. Lele, who are pediatric dentists in Tucson, ... fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the patient ...
(Date:11/24/2015)... , ... November 24, 2015 , ... In an ... restrictions and variables that determine which patients are or are not eligible for bariatric ... have a BMI over 40, are more than 100 pounds overweight, or have a ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... national leaders when it comes to several aspects of orthopedic care. They have ... replacements, orthopedic surgeries and general orthopedic care. , Becker's Hospital Review selected ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ... NASDAQ: EPIX ) announced today that the first ... study of EPI-506 as a treatment for metastatic castration-resistant ... and Canada.  --> ... --> In the Phase 1/2 clinical trial, ESSA ...
(Date:11/24/2015)... --> --> According to ... Type (Bone Graft, Bine Graft Substitute, Platelet Rich Plasma, BMAC), ... Fusion), End User, and Geography - Global Forecast to 2020", ... Billion in 2014 and is expected to reach $2.4 Billion ... period of 2015 to 2020. Browse 55 market ...
Breaking Medicine Technology: